At a glance
ClinicalIndex Comparison RecordN/ACompleted· 716 enrolled
Drug / intervention
Encorafenib +5 moredrug
Likely dose
Encorafenib 450 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United States
In Brief
An observational study evaluating Encorafenib, Binimetinib, and 4 other interventions for Melanoma. Completed, enrolled 716 participants across 1 site.
Detailed Summary
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy. The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedMar 2022
Primary CompletionDec 2023
TodayJul 2026
First PostedMar 2, 2022
Enrollment StartJan 17, 2022
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.3 years ago
Interventions
Encorafenibdrug
450 mg QD
Binimetinibdrug
45 mg BID
Vemurafenibdrug
960 mg BID for 28 days/cycle
Cobimetinibdrug
60 mg QD for 21 days/cycle
Dabrafenibdrug
150 mg BID
Trametinibdrug
2 mg QD